Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Within-Subject Randomised, Placebo-Controlled, Proof of Concept, Comparison Study of SHP-141C Topical Cream in Psoriasis, Using the Microplaque Assay.

X
Trial Profile

A Double-Blind, Within-Subject Randomised, Placebo-Controlled, Proof of Concept, Comparison Study of SHP-141C Topical Cream in Psoriasis, Using the Microplaque Assay.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Aug 2014

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remetinostat (Primary) ; Betamethasone; Calcipotriol
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Shape Pharmaceuticals; TetraLogic Pharmaceuticals
  • Most Recent Events

    • 10 Jul 2014 A protocol has been amended to change the concentration of drugs: Betamethasone- 0.02%, Calcipotriol - 0.005% and SHP-141C - 0.5%, 1.0% and 2.0%.
    • 10 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 Feb 2013 Planned End Date changed from 1 Feb 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top